» Articles » PMID: 22795504

Prevalence of Airway and Parenchymal Abnormalities in Newly Diagnosed Rheumatoid Arthritis

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2012 Jul 17
PMID 22795504
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Pulmonary disease is a well recognised and important extra-articular manifestation of rheumatoid arthritis (RA). The objective of this study was to determine the prevalence of airway and parenchymal abnormalities in newly diagnosed patients with RA and to correlate these with clinical measures of RA severity and laboratory tests.

Methods: 60 patients with a new (symptom duration <12 months) diagnosis of RA (43 females, 42 European, mean age 54, 33 ever smoker, (17 current) underwent lung function testing and high resolution computed tomography (HRCT) scored by two independent radiologists.

Results: Eighteen (30%) patients reported respiratory symptoms: dyspnoea (11), cough (11), and wheeze (8). Twelve (20%) patients had physiologic evidence of airflow obstruction and 24 (40%) had reduced gas transfer. The prevalence of HRCT abnormalities (in any lobe) was as follows: decreased attenuation 67%, bronchiectasis 35%, bronchial wall thickening 50%, ground glass opacification 18%, reticular changes 12%. All abnormalities were more common in the lower lobes. With the exception of reduced DLCO, there were no significant differences in the prevalence of HRCT patterns or lung function parameters between smokers and non smokers. Anti-CCP antibodies and rheumatoid factor (RF) correlated strongly with DLCO and variably with other physiologic measures but poorly with radiologic abnormalities.

Conclusion: Patients with newly diagnosed RA have a moderate prevalence of airway and parenchymal abnormalities on HRCT and lower than predicted lung function parameters which cannot entirely be explained by smoking. These data suggest that pulmonary involvement is present early in the disease course in RA.

Citing Articles

Mortality and Predictive Factors for Death Following the Diagnosis of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Retrospective, Long-Term Follow-Up Study.

Mori S, Sakai F, Hasegawa M, Nakamura K, Sugahara K J Clin Med. 2025; 14(4).

PMID: 40004909 PMC: 11855988. DOI: 10.3390/jcm14041380.


Fibroblasts in rheumatoid arthritis: novel roles in joint inflammation and beyond.

Neofotistou-Themeli E, Goutakoli P, Chanis T, Semitekolou M, Sevdali E, Sidiropoulos P Front Med (Lausanne). 2025; 11:1376925.

PMID: 39906351 PMC: 11790453. DOI: 10.3389/fmed.2024.1376925.


Exploring rheumatoid arthritis associated interstitial lung disease a retrospective study from two Saudi tertiary care centers.

Boudal A, Alsaigh R, Alrajhi N, Idrees M, Omair M, Al Rayes H BMC Rheumatol. 2024; 8(1):32.

PMID: 39103942 PMC: 11299410. DOI: 10.1186/s41927-024-00403-9.


Genetic evidence reveals a causal relationship between rheumatoid arthritis and interstitial lung disease.

Zhao R, Zhang Y, Guo J, Qiao J, Song S, Zhang T Front Genet. 2024; 15:1395315.

PMID: 38808332 PMC: 11130360. DOI: 10.3389/fgene.2024.1395315.


Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development.

Jeong E, Hong H, Lee Y, Kim K Int J Mol Sci. 2024; 25(5).

PMID: 38473928 PMC: 11154459. DOI: 10.3390/ijms25052682.